secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2024-08-28T23:59:59+00:00
Accession:  0000950170-24-101395
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director David Lucchino resigns; Katharine Knobil appointed to board
--------------------------------------------------------------------

- David Lucchino resigned from board effective Aug 26, 2024; no disagreement with management or board.
- Lucchino signed consulting agreement: $9k/quarter through 2026 annual meeting, then $2k/quarter through 2027; option grant (~$150k, capped 8k shares) at 2025 meeting, vesting at 2026 meeting.
- Board reduced size from 7 to 6, then increased to 7 to appoint Katharine Knobil, M.D. as Class III director; also appointed to Compensation Committee.
- Dr. Knobil will serve until 2025 annual meeting; receives standard non-employee director compensation and indemnification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/0000950170-24-101395-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/krro-20240826.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-101395

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer